Organization (Hospital)
Elazığ Mental Health and Diseases Hospital
ClinicalTrials.gov lists Elazığ Mental Health and Diseases Hospital as lead sponsor of 13 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
18 sections measured, none recorded
This page covers Elazığ Mental Health and Diseases Hospital: 13 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (13)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Psychotic Disorders | 4 |
| Anxiety Disorders | 2 |
| Bipolar Disorder | 2 |
| Panic Disorder | 2 |
| Conversion Disorder | 1 |
Showing 5 of 13 disease areas.
Trials by start year as sponsor or collaborator (3)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 9 |
| 2024 | 1 |
No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 3 hit target (n=3) | 2 of 3 on time (n=3) |
Journals published in (24)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Drug and alcohol dependence | 2 |
| Journal of affective disorders | 2 |
| The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry | 2 |
| Addiction & health | 1 |
| Anticancer research | 1 |
Showing 5 of 24 journals.
Latest dated events (13)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 13 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD7 | Trial sponsor | Named in trial inclusion criteria |
| TAS1R3 | Trial sponsor | Named in trial exclusion criteria |
| CD7 | Trial sponsor | Mentioned in trial text |
| TAS1R3 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.